Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019163 (hepatitis B)
 38,309 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

In this paper results obtained with thymostimulin (TP-1 Serono) in patients with hepatitis B surface antigen (HBsAg)-positive chronic active hepatitis after 2 years follow-up are reported. The favourable trend observed in a previous trial was confirmed after a longer observation period, most patients showing a significant amelioration of clinical, biochemical and histological parameters, with respect to control group. Hepatitis B virus (HBV) serology, too, showed a significantly higher rate of seroconversion and antigen disappearance in treated patients. Finally, hospitalization period of the latter was significantly lower. These results, though obtained in a small population of patients, seem to indicate a role for thymic hormone therapy in the management of chronic active hepatitis.
 ...
PMID:Thymostimulin in the treatment of hepatitis B surface antigen-positive chronic active hepatitis. Controlled clinical trial--two years follow-up. 330 Jun 64

The results of this controlled trial with thymostimulin (TP-1 Serono) on hepatitis B surface antigen (HBsAg)-positive chronic active liver disease (CALD), involving 34 consecutive patients chosen by predefined criteria and randomly allocated to control and treatment groups, show that this thymic hormone may significantly improve the clinical, biochemical, serological and immunological parameters of this disease, and ameliorate the quality of the patients' life. The treatment schedule was adjusted according to the immunological response. Our study population was too small to enable any conclusions to be drawn: further studies are therefore required to establish the exact role of thymostimulin in the treatment of HBsAg-positive CALD.
 ...
PMID:Effectiveness of thymostimulin treatment in hepatitis B surface antigen-positive chronic active liver disease. Results of a randomized clinical trial. 390 42